• Cyril Rivat and Jane Ballantyne.
• Université de Montpellier, Montpellier, France, Institut des Neurosciences de Montpellier, INSERM U1051, Montpellier, France.
• Pain Rep. 2016 Aug 1; 1 (2): e570.

IntroductionIn the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer.ObjectivesWe aimed to examine the published literature on basic science explaining pronociceptive opioid actions, and apply this knowledge to clinical observation.MethodsWe reviewed the existing literature on the pronociceptive actions of opioids, both preclinical and clinical studies.ResultsBasic science provides a rationale for the clinical observation that opioids sometimes increase rather than decrease pain. Central sensitization (hyperalgesia) underlies pain chronification, but can also be produced by high dose and high potency opioids. Many of the same mechanisms account for both central pain and opioid hyperalgesia.ConclusionNewly revealed basic mechanisms suggest possible avenues for drug development and new drug therapies that could alter pain sensitization through endogenous and exogenous opioid mechanisms. Recent changes in practice such as the introduction of titration-to-effect for opioids have resulted in higher doses used in the clinic setting than ever seen previously. New basic science knowledge hints that these newer dosing practices may need to be reexamined. When pain worsens in a patient taking opioids, can we be assured that this is not because of the opioids, and can we alter this negative effect of opioids through different dosing strategies or new drug intervention?

4 keywords...

hide…